On December 29, Sino Biopharmaceutical Limited (1177.HK) announced that the Phase II clinical trial of TQH3906 (a TYK2/JAK1 JH2 allosteric inhibitor), a Class 1 innovative drug independently developed by CTTQ Pharma for moderate-to-severe Plaque Psoriasis (PsO), has met its primary endpoint. Study results showed that at the recommended Phase 2 dose (RP2D), after 12 weeks of treatment, the PASI 75 (Psoriasis Area and Severity Index score reduction of at least 75% from baseline) response rate exceeded 90%, and the PASI 90 (Psoriasis Area and Severity Index score reduction of at least 90% from baseline) response rate exceeded 70%.

On December 25, Sino Biopharmaceutical Limited (1177.HK) received a drug registration certificate from the National Medical Products Administration (NMPA) for the tenth indication of its Class 1 innovative drug, Anlotinib Hydrochloride Capsules (Fukewei®).

On December 19, at the "2025 TVB Environmental, Social, and Governance (ESG) Awards Presentation Ceremony" held in Hong Kong, organized by TVB and co-organized by the Hong Kong Productivity Council, Sino Biopharmaceutical Limited (1177.HK) was honored with the "ESG Social Innovation Science and Technology Award" for its innovative practices in carbon neutrality strategy and climate risk governance.

On December 16, the "2025 Science and Technology + New Quality Productive Forces Summit", organized by the Hong Kong China Friendship Association, was held in Hong Kong.

On December 11, the world's first CDK2/4/6 inhibitor, Culmerciclib Capsules (Saitanxin®), received a drug registration approval letter from the National Medical Products Administration (NMPA).

At the 2025 American Society of Hematology (ASH) Annual Meeting, Sino Biopharm (1177.HK) announced the Phase I study results for TQB2934 for injection (a BCMA×CD3 bispecific antibody) in treating patients with relapsed/refractory multiple myeloma (R/R MM) in a poster presentation.

At the 67th American Society of Hematology (ASH) Annual Meeting (2025 ASH), Chia Tai Tianqing, a core enterprise of Sino Biopharm (1177.HK), presented the latest clinical study data on the Class 1 innovative drug Rovadicitinib (a JAK/ROCK inhibitor) in combination with a BET inhibitor (TQB3617) for the treatment of myelofibrosis (MF) in an oral presentation.